Endo Names Paul Campanelli President and Chief Executive Officer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/14/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to Endo Names Paul Campanelli President and Chief Executive Officer

Oppenheimer Remains Sidelined Following Endo Int'l's (ENDP) New CEO Appointment

September 26, 2016 10:04 AM EDT

Oppenheimer reiterated a Perform rating on Endo International plc (NASDAQ: ENDP), following the company's announced appointment of Paul Campanelli to president and chief executive officer. Mr. Campanelli joined ENDP in 2015 through the acquisition of Par Pharmaceuticals and most recently served as the CEO of Par. Mr. Campanelli's... More

Piper Jaffray Reiterates Neutral as Endo Int'l (ENDP) Announces Paul Campanelli as New CEO

September 26, 2016 8:26 AM EDT

Piper Jaffray reiterated a Neutral rating and $19.00 price target on Endo International plc (NASDAQ: ENDP) following the company's announcement appointment of Paul Campanelli as CEO effective immediately. Mr. Campanelli was responsible for the 2014 acquisition of JHP Pharma, which gave Par a sizable generic injectibles business and more importantly gave the... More

Leerink Not Surprised by CEO Change at Endo Int'l (ENDP); Affirms at 'Market Perform'

September 23, 2016 8:48 AM EDT

Leerink affirms Endo Int'l (Nasdaq: ENDP) at Market Perform with a price target of $22 following news of a key executive change.

The firm commented today, This morning ENDP announced that Rajiv De Silva will step down as CEO and be replaced... More